See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

āshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)

Summary by The Huntsville Item
BRISBANE, Calif.--(BUSINESS WIRE)--Jun 24, 2025-

2 Articles

The Huntsville ItemThe Huntsville Item
Lean Left

āshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)

BRISBANE, Calif.--(BUSINESS WIRE)--Jun 24, 2025-

Read Full Article
Clinical Trials ArenaClinical Trials Arena

āshibio begins dosing in trial of andecaliximab for spinal cord injury

āshibio has commenced subject dosing in the Phase Ib trial, ANDECA-HO, assessing andecaliximab in spinal cord injury (SCI) patients.The post āshibio begins dosing in trial of andecaliximab for spinal cord injury appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Huntsville Item broke the news in on Tuesday, June 24, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Brisbane icon

Brisbane

News
For You
SearchBlindspotLocal